{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:54:40Z","timestamp":1790985280932,"version":"4.1.0"},"reference-count":36,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,12,19]],"date-time":"2012-12-19T00:00:00Z","timestamp":1355875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Present interferon\u2010based therapy for chronic hepatitis <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content> is limited by both efficacy and tolerability. Telaprevir and boceprevir are the first two direct\u2010acting antiviral drugs (<jats:styled-content style=\"fixed-case\">DAAs<\/jats:styled-content>) that inhibit hepatitis <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content> virus replication to be licensed for use in conjunction with pegylated interferon and ribavirin. Numerous other <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>s are in clinical development, and phases 2 and 3 trials are evaluating interferon\u2010free combination <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content> therapy. Interferon\u2010free sustained virologic responses have now been achieved with combinations of asunaprevir and daclatasvir; sofosbuvir and ribavirin; sofosbuvir and daclatasvir; faldaprevir and <jats:styled-content style=\"fixed-case\">BI<\/jats:styled-content>207127; <jats:styled-content style=\"fixed-case\">ABT<\/jats:styled-content>\u2010450, ritonovir and <jats:styled-content style=\"fixed-case\">ABT<\/jats:styled-content>\u2010333; <jats:styled-content style=\"fixed-case\">ABT<\/jats:styled-content>\u2010450, ritonovir and <jats:styled-content style=\"fixed-case\">ABT<\/jats:styled-content>\u2010072; miracitabine, danoprevir and ritonavir; and alisporivir and ribavirin. Some drugs are genotype\u2010specific in their activity, whereas others are pan\u2010genotypic, and differential responses for the genotype 1 subtypes 1a and 1b have emerged with many <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content> combinations. Viral breakthrough and resistance are important considerations for future trial design. The prospect of interferon\u2010free combination <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content> therapy for hepatitis <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content> virus is now finally becoming a reality.<\/jats:p>","DOI":"10.1111\/jgh.12028","type":"journal-article","created":{"date-parts":[[2012,11,9]],"date-time":"2012-11-09T09:47:55Z","timestamp":1352454475000},"page":"38-45","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Current prospects for interferon\u2010free treatment of hepatitis <scp>C<\/scp> in 2012"],"prefix":"10.1111","volume":"28","author":[{"given":"Catherine AM","family":"Stedman","sequence":"first","affiliation":[{"name":"Christchurch Hospital  Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,12,19]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_11_3_1","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jhep.2004.02.007","article-title":"Peginterferon alfa\u20102b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3","volume":"40","author":"Zeuzem S","year":"2004","journal-title":"J. Hepatol."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.05.032"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.07.013"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23192"},{"issue":"2","key":"e_1_2_11_9_1","first-page":"A8","article-title":"Safety of telaprevir or boceprevir in combination with peginterferon alfa\/ribavirin, in cirrhotic non responders. First results of the French Early Access Program (ANRS CO20\u2010CUPIC)","volume":"56","author":"Hezode C","year":"2012","journal-title":"J. Hepatol."},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2011.627851"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)60010-5"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.020"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24262"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3000544"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61384-0"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.08.051"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24744"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104430"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24724"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)60028-2"},{"key":"e_1_2_11_21_1","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","author":"Gane EJ","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_11_22_1","unstructured":"SulkowskiMS GardinerDF Rodriguez\u2010TorresMet\u2009al.High rate of sustained virologic response with the all\u2010oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor) with or without ribavirin in treatment\u2010naive patients chronically infected with HCV genotype 1 2 or 3. Program and abstracts of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases; Boston MA 9\u201013 November 2012; Abstract LB\u20102"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)60021-X"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(11)61365-2"},{"issue":"4","key":"e_1_2_11_25_1","first-page":"1435A","article-title":"VX\u2010222\/telaprevir in combination with peginterferon\u2010alfa\u20102a and ribavirin in treatment\u2010na\u00efve genotype 1 HCV patients treated for 12 weeks: Zenith study, SVR12 interim analysis","volume":"54","author":"Nelson DR","year":"2011","journal-title":"Hepatology"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)60115-9"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61410-X"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)60027-0"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61423-8"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61416-0"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.447"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08309"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.12.057"},{"issue":"2","key":"e_1_2_11_34_1","first-page":"A1420","article-title":"The efficacy and safety of the interferon\u2010free combination of BI201335 and BI207127 in genotype 1 HCV patients with cirrhosis: interim analysis from SOUND\u2010C2","volume":"56","author":"Soriano V","year":"2012","journal-title":"J. Hepatol."},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.11.055"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01317-07"},{"key":"e_1_2_11_37_1","unstructured":"OsinusiA HeytensL LeeYet\u2009al.High efficacy of GS\u20107977 in combination with low or full dose ribavirin for 24 weeks in difficult to treat HCV infected genotype 1 patients: interim analysis from the SPARE trial. Program and abstracts of the 63rd Annual Meeting of the american Association for the Study of Liver Diseases; Bodyon MA 9\u201013 November 2012; Abstract LB\u20104."}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjgh.12028","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjgh.12028","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgh.12028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T02:19:37Z","timestamp":1697336377000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jgh.12028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,19]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1111\/jgh.12028"],"URL":"https:\/\/doi.org\/10.1111\/jgh.12028","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,19]]},"assertion":[{"value":"2012-11-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-12-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}